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Sanlam’s CEO, Johan van Zyl, has admitted 
that his company made a ‘mistake’ in holding 
onto what grew into about R600 million in 
reserves for two major medical aids it once 
owned and ran, but denied being deliberately 
obstructive towards them in the courts.
He was responding to claims by Leon 
Bester, CEO of Selfmed, which together 
with TopMed launched proceedings against 
Sanlam 8 years ago after it divested itself of the 
companies but held onto their considerable 
reserves. This led to widespread reports that 
Sanlam had ‘stripped’ or ‘plundered’ the 
smaller companies along the controversial 
lines of several other retirement funds it 
managed, but Van Zyl vehemently denied this. 
This January three retired judges, on appeal 
arbitration, ruled in favour of the smaller 
companies, finding that Sanlam had from 
May 1975 until December 1997 conducted 
business in a ‘bona fide but mistaken belief 
that the businesses were its own’.
Judges Gerald Friedman, Johan Conradie 
and Peet Nienaber (a former life assurance 
ombudsman) ruled that in terms of the 
changed legislation Sanlam were acting as 
agents for the companies. This mistaken 
belief arose from legal exemptions granted in 
1975 to Sanlam by the Registrar of Medical 
Schemes which it believed to be valid – but 
were not. Van Zyl told Izindaba: ‘Throughout 
that period we asked the Registrar six or 
seven times if the exemptions were valid and 
got the OK on them’.
Interest overtook investments
Although the ruling itself made details of the 
award confidential, Van Zyl put figures to the 
award split, but in historical terms, revealing 
that TopMed got R200 million and Selfmed 
R56 million. He explained that when interest 
was added over the 22-year period, the joint 
amount totalled R600 million, making the 
interest more than the principal amount. One 
leak to MoneyWeb put the final payments as 
R458 million to TopMed and R129 million to 
Selfmed (a total of R587 million). Bester said 
he would ‘never conduct business towards 
his members the way Sanlam did to theirs’ 
(a large portion of the medical aid clients 
are Sanlam employees and in fact ran the 
medical aid companies under the Sanmed 
umbrella in Sanlam).
‘I was the one who signed the affidavits as 
chair of the Selfmed board of trustees and 
was then made aware of what had happened. 
I sat through every minute of every hour 
of every day, so sure it’s emotional and 
personal,’ he added. Bester said both small 
medical aids had been mutual organisations 
and ‘if Sanlam made money out of that based 
on some piece of legislation then surely it 
belongs to the members of Sanlam? How is 
it possible to be a mutual organisation for 
the benefit of members and then they don’t 
get it? Suddenly the mutuality goes for a ball 
of chalk and it’s not for the benefit of the 
members,’ a still angry Bester told Izindaba.
Van Zyl said the money (TopMed and 
Selfmed claimed for R1.5 billion) was never 
taken out of Sanmed because of the dispute 
and denied using the courts to delay, obstruct 
or avoid payment.
‘We didn’t “strip” medical aid reserves’ – 
Sanlam CEO
Sanlam’s CEO Johan van Zyl.
             Picture: courtesy of Sanlam.
This January three retired judges, 
on appeal arbitration, ruled in 
favour of the smaller companies, 
finding that Sanlam had from 
May 1975 until December 1997 
conducted business in a ‘bona 
fide but mistaken belief that the 
businesses were its own’.
IZINDABA
158 March 2011, Vol. 101, No. 3  SAMJ
Sanlam’s employee/claimants 
made the mistake – Van Zyl
‘I would have come to the party far quicker 
except that it was a really big claim dating 
back to 1972 and earlier, and none of us had 
all the facts. The people responsible for the 
mistakes were those who took the premiums 
– we had a health business which we sold off 
and six years later those two schemes, which 
were a big part, came back to us. All those 
were our staff.  The people who claimed 
were the people, who before we sold, ran our 
business,’ he reiterated. ‘So it’s a very difficult 
issue. We had the books, facts and figures – 
but it was very difficult to discern what the 
actual facts were so we had to go through the 
legal process,’ he said. Legal costs, amounting 
to well over R3 million, were awarded to the 
medical aid companies. Van Zyl said Sanlam 
de-mutualised in 1998 – meaning that all 
past profits were given to the people who 
owned the company. That windfall value 
had been ‘dished out to all the folk who did 
business with us – it’s not as if the company 
now sits with the stuff – to throw mud in 
retrospect is invidious’.
Sanlam had appealed against a verdict 
favouring the medical aids because ‘the 
logical question was, this was a hell of a 
long time. You (the Sanlam employees and 
managers of Sanmed) were there all the 
time, you should have known whether this 
was still valid or not. If the exemption had 
expired, Sanlam wouldn’t want to be seen 
as taking people’s money. It’s a big number, 
we wanted an appeal to make sure the 
question was right, then we said OK, if 
we were your agents, let’s reconstruct the 
books; there was no agreement for admin 
expenses, for example: we’d like a reasonable 
remuneration even if it was to run things on 
their behalf. So that was worked in, as was 
income tax and we argued that if you took 
it all into account, the figure comes to zero.’ 
Van Zyl said that what Sanlam did was at 
first legally authorised but when the 1975 
Medical Aids Fund Act came in, ‘that’s when 
the mistake was made’.
‘Sanlam were wrong, but not 
perverse’ – TopMed
Len Deacon, who became principal officer 
of TopMed just over 2 years ago, said what 
Sanlam did was not perverse. ‘They really 
believed they were acting correctly for their 
own account and not as our agents. We 
believed they were contracted as our agents 
and operating for our account. When in 
1998 two boards of trustees were created 
independently of Sanlam under my leadership 
as the CEO/PO of both schemes, we found 
we had zero reserves and questioned that. 
They said we had no right to the reserves 
created over many years by our members 
and we said no ways, you were acting as an 
agent!’ He promised his membership (26 500 
beneficiaries), which atrophied along with 
Selfmed after the demarcation of fiduciary 
responsibilities and independence, that 
contributions would be kept down as much 
as possible and the new-found resources used 
to better manage health risks for the benefit 
of existing members. His membership has a 
40-plus age profile.
Bester said the security of his 19 500 
beneficiaries, most of whom had ‘stuck with 
the company through thick and thin’, was 
paramount. It was ‘too early’ to say whether 
they’d get better benefits but a probe of 
how much new investment income would 
generate would determine what, if anything, 
would be passed on to members. ‘We can’t 
afford to be too splashy ‘coz you can wipe out 
a surplus in 4 - 5 years and distort your base 
beyond repair,’ he stressed. TopMed now has 
over 150% in reserves and Selfmed about 
95%, making them the envy of most of their 
competitors.
Van Zyl told Izindaba that, at the time of 
going to print, Sanlam was wrapping up final 
negotiations around indemnifying Sanlam 
and associated companies and ensuring the 
claim only went against the dormant Sanmed 
in return for a sweeter deal.
‘We’re seeing if we can’t help them on asset 
management because if we pay cash they’ll 
have to buy stocks and bonds and there’s a 
lot of money in those already. We might gain 
them an extra five per cent which is about 
an extra R50 million. It’s been a long process 
and purely in hindsight, the moment you get 
the answer it seems obvious,’ he quipped.
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